|
A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Hansoh Pharma |
Research Funding - Hansoh Pharma (Inst) |
|
|
Employment - Betta Pharmaceuticals |
Leadership - Betta Pharmaceuticals |
Stock and Other Ownership Interests - Betta Pharmaceuticals |
|
|
No Relationships to Disclose |